Alvotech

ALVO

Company Profile

  • Business description

    Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

  • Contact

    9, rue de Bitbourg
    LuxembourgL-1273
    LUX

    T: +352 4224500

    https://www.alvotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    1,460

Stocks News & Analysis

stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks

ASX energy share remains cheap despite strong outlook

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks

Moated AI-proof tech play hiding in the ASX 100

ChatGPT and large language models should be a tailwind for this company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.4019.00-0.21%
CAC 408,157.8269.50-0.84%
DAX 4024,128.9826.47-0.11%
Dow JONES (US)49,230.7179.61-0.16%
FTSE 10010,379.0877.93-0.75%
HKSE25,978.0762.870.24%
NASDAQ24,836.60398.101.63%
Nikkei 22559,716.18575.950.97%
NZX 50 Index12,874.949.99-0.08%
S&P 5007,165.0856.680.80%
S&P/ASX 2008,786.5012.10-0.14%
SSE Composite Index4,079.9013.35-0.33%

Market Movers